Results 171 to 180 of about 286,873 (209)

Pharmacokinetics and Pharmacodynamics of a Sustained-Release Dexamethasone Intravitreal Implant

Investigative Ophthalmology and Visual Science, 2011
To determine the pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone (DEX) intravitreal implant (Ozurdex; Allergan, Inc.).Thirty-four male monkeys (Macaca fascicularis) received bilateral 0.7-mg DEX implants. Blood, vitreous humor, and retina samples were collected at predetermined intervals up to 270 days after administration ...
Scott M Whitcup, Michael R Robinson, Baruch D Kuppermann   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

MIGRATION OF INTRAVITREAL DEXAMETHASONE IMPLANT TO ANTERIOR CHAMBER

RETINAL Cases & Brief Reports, 2013
Purpose: To describe two cases of migration of intravitreally injected dexamethasone implant into the anterior chamber. Methods: Charts were reviewed of two patients who received sustained-release dexamethasone implant intravitreally for chronic intractable cystoid macular edema.
Vamsi K, Gullapalli, David A, DiLoreto
openaire   +2 more sources

Intravitreal dexamethasone implants for non‐infectious uveitis

Clinical & Experimental Ophthalmology, 2019
AbstractImportanceInflammatory‐mediated cystoid macular oedema (CMO) is the most common inflammatory‐mediated threat to vision in non‐infectious uveitis (NIU). Corticosteroid therapy is the cornerstone to the management of CMO in NIU. Sustained‐release dexamethasone (DEX) implant devices provide localized therapy.BackgroundThe authors present a series ...
Matthew McCartney, Peter McCluskey, Sophia Zagora   +2 more
openaire   +2 more sources

Pharmacologic and clinical profile of dexamethasone intravitreal implant

Expert Review of Clinical Pharmacology, 2012
The challenge in the treatment of chronic retinal diseases is to deliver effective therapy to the target tissues in the back of the eye while limiting drug exposure in nontarget tissues. Intravitreal placement provides the most targeted drug delivery, but repeated penetration of the globe to deliver intravitreal therapy can pose safety risks.
Michael R, Robinson, Scott M, Whitcup
openaire   +2 more sources

Intravitreal dexamethasone implant for noninfectious uveitis in Chinese patients

International Ophthalmology, 2022
To evaluate the effectiveness and safety of the dexamethasone intravitreal implant (DEX-I) in Non-Infectious Uveitis (NIU) in Chinese patients.Ninety-one eyes of 77 patients (56 men, 21 women) receiving 130 implant injections for NIU were included. Treatment indication, uveitis diagnosis, best-corrected visual acuity (BCVA), central retinal thickness ...
Shun Zeng, Li Yang, Feng Bai, Tao Liu, Xiaoli Liu   +4 more
openaire   +2 more sources

Intravitreal Dexamethasone Implant for Treatment of Sarcoidosis-Related Uveitis

Advances in Therapy, 2019
To assess the efficacy and safety of intravitreal dexamethasone implant injection in the management of sarcoidosis-related uveitis.A retrospective analysis was performed of the efficacy and safety of intravitreal dexamethasone implant injection for indications such as intractable vitritis, vasculitis, or cystoid macular edema.This study comprised 20 ...
Mirinae Kim, Seong Ah Kim, Wookyung Park, Rae Young Kim, Young-Hoon Park   +4 more
openaire   +2 more sources

Intravitreal Dexamethasone Implant for the Treatment of Postoperative Macular Edema

Ophthalmologica, 2016
<b><i>Introduction:</i></b> Macular edema after cataract surgery (Irvine-Gass syndrome) or pars plana vitrectomy is a postoperative complication which can lead to permanent visual loss. Increased inflammatory substances, such as prostaglandins and cytokines, are discussed to be causative.
André, Klamann, Katharina, Böttcher, Philipp, Ackermann, Gerd, Geerling, Marc, Schargus, Rainer, Guthoff   +5 more
openaire   +2 more sources

Dexamethasone: intravitreal implant.

Prescrire international, 2011
Macular oedema is one of the complications of retinal vein occlusion. About half of the patients recover spontaneously within 3 to 6 months. There is currently no drug that improves outcome. An intravitreal implant delivering 0.7 mg of dexamethasone has been authorised for the treatment of macular oedema in this setting. Clinical assessment is based on
openaire   +1 more source

Intravitreal dexamethasone implant in radiation-induced macular oedema

British Journal of Ophthalmology, 2017
To evaluate the efficacy and duration of activity of a single intravitreal dexamethasone implant in patients affected by radiation maculopathy.Thirteen consecutive eyes of 13 patients affected by radiation maculopathy secondary to eye irradiation for a primary uveal melanoma (Iodine-125 brachytherapy) and treated with a single intravitreal 0.7 mg ...
Frizziero, Luisa, PARROZZANI, RAFFAELE, Trainiti, Sara, PILOTTO, ELISABETTA, Miglionico, Giacomo, Pulze, Serena, MIDENA, EDOARDO   +6 more
openaire   +2 more sources

Dexamethasone Intravitreal Implant for Noninfectious Intermediate or Posterior Uveitis

Archives of Ophthalmology, 2011
To evaluate the safety and efficacy of 2 doses of dexamethasone intravitreal implant (DEX implant) for treatment of noninfectious intermediate or posterior uveitis.In this 26-week trial, eyes with noninfectious intermediate or posterior uveitis were randomized to a single treatment with a 0.7-mg DEX implant (n = 77), 0.35-mg DEX implant (n = 76), or ...
Careen, Lowder, Rubens, Belfort, Sue, Lightman, C Stephen, Foster, Michael R, Robinson, Rhett M, Schiffman, Xiao-Yan, Li, Harry, Cui, Scott M, Whitcup   +8 more
openaire   +2 more sources